Скачать или смотреть $7.3 Million Boost for Nipah Virus Vaccine: ChAdOx1 NipahB Development Explained

The Nipah virus is one of the deadliest pathogens known to humanity, with a fatality rate of up to 75%. Despite its threat, no preventive vaccines exist—until now. In a groundbreaking collaboration, the Coalition for Epidemic Preparedness Innovations (CEPI), the University of Oxford, and the Serum Institute of India (SII) are developing the ChAdOx1 NipahB vaccine candidate. This video breaks down the $7.3 million funding, the vaccine's potential impact, and how it could save lives in Nipah-affected regions like Bangladesh and India. Learn about the Phase II clinical trials, the investigational reserve of 100,000 doses, and the global efforts to combat this deadly virus. Stay informed about the latest advancements in pandemic preparedness and vaccine development. Keywords: Nipah virus, ChAdOx1 NipahB, CEPI, Serum Institute of India, vaccine development, pandemic preparedness, global health.